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Anaemias are a common threat to very low birth weight infants and a 
major problem in the intensive care of preterm infants. Contributing factors 
include anaemia of prematurity and blood losses. The major cause of anaemia 
of prematurity is an abrupt increase in oxygen availability after transition from 
placental to pulmonary oxygenation with a consequent decrease in erythro-
poietin (EPO) production. As anaemia develops there is a diminished EPO 
response to decreased oxygen availability. Additionally there is more rapid 
destruction of fetal cells. Due to rapid growth between 30 and ^ w e e k s ' 
gestation there may also be haemodilution [1, 2]. Blood loss may be due to 
spontaneous perinatal haemorrhage, but the most significant cause of anae-
mia in the first weeks of life is diagnostic sampling. The smallest preterm 
infants requiring the highest level of intensive care may have their total blood 
volume removed for sampling within the first 28 days of life [3]. The view has 
become obsolete that anaemia is 'physiologic' in preterm infants [4]. It reduces 
the amount of available oxygen [5] and contributes to apnoeic spells, mesen-
teric hypoperfusion [6], necrotizing enterocolitis, and failure to thrive [7]. 
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Infants of less than 1,000 g birth weight requiring artificial ventilation will 
need frequent red cell transfusions. Therefore, they may be confronted with 
more than 8 donors within 28 days and thus the risk of acquiring viral in-
fections is significant. 'Walking' donor systems, using a constant donor -
preferably the infant's father - [8], do not exclude the risk of transfusion-
acquired viral infections. Infants who are allowed to become anaemic may be 
symptomatic [9]. The best descriptors of this anaemia are red cell volume and 
haematocrit [10]. Infants with higher red cell volumes at birth require a shorter 
period of intensive care and have reduced morbidity and mortality. 
Red cell volume can be manipulated by controlled placento-fetal trans-
fusion at birth [11] or transfusion of adult red cells. Successful stimulation of the 
infant's own erythropoiesis will maintain red cell volume, i.e. the total amount 
of red cells in the circulation, thus reducing the need for red cell transfusion in 
the period of intensive care and prevent the anaemia of prematurity. 
Recent studies have suggested that erythroid progenitors from preterm 
infants differentiate in response to recombinant human EPO (rhEPO) [12,13]. 
rhEPO has been used successfully to stimulate erythropoiesis in more than 
2,000 adults and children with anaemia due to renal failure [14,15]. The aim of 
this study was to investigate whether treatment with rhEPO reduces the 
anaemias of prematurity and thus the need for transfusion by one third in 
preterm infants. 
Patients, Materials and Methods 
Ethical approval and informed consent was obtained by each participating centre. 171 
preterm infants with gestational age of 28-32 completed weeks were admitted to the five study 
centres from April 1989 to February 1990. 47 infants were not eligible for study due to 
participation in other therapeutic trials (n = 28) or lack of parental consent (n = 19). 31 
preterm infants were excluded prior to randomization for the following reasons: polycythae-
mia (venous haematocrit 55% or higher on 3rd day of life, regardless of cause), n = 10; 
congenital malformation, n = 8; haemolytic disease of the newborn, n = 3; exchange trans-
fusion, n = 2; renal failure (urine output <30 ml/kg/24 h and/or serum creatinine >180 ^mol/1 
on 3rd day of life), n = 2; other reasons (e.g. investigator absent), n = 6. 
A total of 93 preterm infants were entered in the study. Details are shown in table 1. The 
study was of randomized open-controlled parallel-group design. Stratification was performed 
according to the need for ventilatory support on the 3rd day of life. Randomization was 
performed by prenumbered sealed envelopes. 
EPO Treatment. rhEPO was supplied from Boehringer Mannheim GmbH in vials 
containing 500 U/ml in liquid preparation. A volume of 0.1 ml of the preparation was diluted 
with 0.9 ml 0.15 M NaCl and a dose of 30 U/kg was given by subcutaneous injection into the 
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Table 1. Randomized patients according to stratification, birth weight, and gestational age 
rhEPO 
n = 43 
Control 
n = 50 
Male/female, n 27/16 29/21 
Birth weight, g (mean ± SD) 1,380 ±324 1,295 ±323 
500- 999 g (n, vent/spont) 7/2 5/4 
1,000-1,499 g (n, vent/spont) 9/11 10/17 
s l , 5 0 0 g (n, vent/spont) 6/8 8/6 
Gestational age, weeks (mean ± S D ) 30 ± 1 30 ± 1 
28 weeks, n 3 3 
29 weeks, n 5 11 
30 weeks, n 16 13 
31 weeks, n 19 22 
32 weeks, n 0 1 
rhEPO = rhEPO-treated group; Control = 
spont = spontaneous breathing. 
control group; vent = artificial ventilation; 
thigh every 3rd day from the 4th to the 25th day of life. Control infants were not given 
subcutaneous injections of placebo, but were otherwise managed identically. Iron treatment 
was started on day 14 with 2 mg Fe2+/day orally, if there were no feeding or intestinal prob-
lems, and was given in the form of Fe(II)-chloride, Fe(II)-ascorbate or polysaccharide-iron 
complex. 
Patient monitoring: Infants' heart rate, respiratory rate and blood pressure were rec-
orded throughout the study. Monitoring for liver parenchymal damage and renal failure was 
performed on days 3,13, and 25. Ultrasound brain scan for the detection of intraventricular 
haemorrhage and ophthalmoscopy for retinopathy of prematurity was carried out. During the 
study period, rhEPO treatment was withheld if the haematocrit rose to >50% or the hae-
moglobin to >17 g/dl. If these values were achieved by transfusions, and were maintained for 
at least 3 days after the last transfusion, rhEPO administration was discontinued until hae-
moglobin concentration had fallen below a value which was 3 g/dl above the level recom-
mended as indication for transfusion (fig.l) . Moreover, the treatment was stopped if the 
platelet count was >600 x 109/1, and if renal failure, hypertension or severe local reactions 
occurred. Patients were withdrawn from the study if they required an exchange transfusion, or 
medication with possible toxicity to bone marrow. Proven vertical infection and loss of 
parental consent were also indications for withdrawal. 
Transfusion was strictly regulated as shown in figure 1. Volume of transfused red cells 
was determined by multiplying the total transfused volume by the haematocrit of the donor 
pack. Where the haematocrit of the transfused blood was unavailable the red cell volume 
transfused was calculated using a donor haematocrit of 70%. Transfused volume was divided 
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Yes 
No 
1-2 weeks 
3-5 weeks 
No 
vHct < 27%, Hb < 9 g/dl 
requires FiOa > 0.40 
Infant is ventilated 
or 
vHct < 42%, Hb < 14 g/dl 
> 9 ml/kg blood sampled 
since last transfusion 
or 
vHct < 36%, Hb < 12 g/dl 
> 9 ml/kg blood sampled 
since last transfusion 
or 
vHct < 30%, Hb < 10 g/dl 
> 9 ml/kg blood sampled 
since last transfusion 
or 
Symptoms of anaemia 
apnoeic spells, 
distended abdomen, 
failure of thrive 
e.g. 
Fig. 1. Indication for transfusion of packed red cells. 
by birth weight. The total volume of blood removed for diagnostic purposes during the study 
period was carefully recorded. 
Haematological Studies. Venous haematocrit, haemoglobin and platelet counts were 
performed on days 3, 7,10,13,19, and 25 prior to the administration of rhEPO. Reticulocyte 
count, serum ferritin, serum protein and serum EPO were checked on days 3,13, and 25. The 
total volume of blood required for the study was 2,700 jil. 
Statistical Methods. Mean values between groups were tested with the Mann-Whitney 
test. For categorical data the x2 test or Fisher's exact test were used respectively. 
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Table 2. Cumulated packed red cell volume transfused until day 25 
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Red cells transfused, ml/kg Number of infants with/ 
without transfusion 
rhEPO control rhEPO control 
mean SD mean SD 
Spontaneous breathing 6.6 9.1 10.9 14.0 8/11 15/10 
Artificial ventilation 21.2 21.1 22.3 25.8 15/4 14/6 
All 14.1 17.8 16.5 20.8 23/15 29/16 
rhEPO = rhEPO-treated group; control = control group. 
Table 3. Haematologic values on day 25 
Spontaneous breathing Artificial ventilation 
rhEPO, n = 19 control, n = 25 rhEPO, n = 19 control, n = 20 
mean SD mean SD mean SD mean SD 
Hct, % 36 8 38 5 41 6 39 7 
Hb, g/dl 11.8 2.1 12.3 1.5 13.6 2.0 12.7 2.2 
WBC, x 109/1 10.2 2.0 10.3 3.3 10.6 3.8 11.2 3.1 
Platelets, x 109/1 390 149 381 165 318 179 336 162 
Reticulocytes, % 5.0 6.2 3.7 4.8 7.7 14.9 2.5 2.1 
Ferritin, ng/ml 163 74 170 78 252 171 201 90 
rhEPO = rhEPO-treated group; control = control group. 
Results 
Efficacy 
The cumulated volume of red cells transfused within the first 25 days is 
shown in table2. A total of 31 infants (15 rhEPO, 16 control infants) did not 
require any transfusions. There was no significant difference between the two 
groups of infants. The effect of rhEPO treatment on haematological values is 
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Fig. 2. Development of anaemia in preterm infants during the first 25 days of life. 
a Venous haematocrit. b Haemoglobin. Median ± quartiles. No difference can be observed 
between rhEPO-treated ( • ) and control infants ( A ) . 
shown in table 3 and figures 2-4. There was no significant difference in any of 
the parameters among treated and nontreated, ventilated and nonventilated 
infants. Cumulated iron dose up to day 25 is shown in table 4. Although it was 
different in each centre, there were no signs of iron deficiency. Median ferritin 
levels on day 13 (before iron treatment was initiated) were 186 ng/ml in the 
rhEPO group and 189 ng/ml in the control group (NS). Ferritin levels of less 
than 100 ng/ml were never observed during the study period. The serum 
ferritin concentrations remained unchanged throughout the study (fig. 3). 
Total blood volume sampled for diagnostic purpose within 25 days is shown in 
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Fig. 3. Reticulocyte concentration (a) and serum ferritin levels (b) in preterm infants 
during the first 25 days of life. Median ± quartiles. No difference can be observed between 
rhEPO-treated ( • ) and control infants ( A ) . 
figure 5. It is highest in the smallest infants and in each birth weight group is 
higher in infants requiring ventilatory support. 
Safety 
The study was discontinued in 10 infants as shown in table 5. No infant 
developed arterial hypertension (i.e. systolic blood pressure above 90 mm Hg) 
or suffered severe local reaction at the site of injection. The incidence of 
complications reported during the study is shown in table 6. No infant treated 
with rhEPO died. There were two deaths in the control group (one of a 610 g 
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Fig. 4. a Typical rise of platelet count in preterm infants during the first 25 days of life. 
b White blood cell count on days 3 and 25 in preterm infants. Median ± quartiles. No 
difference can be observed between rhEPO-treated ( • ) and control infants ( A ) . 
infant from necrotizing enterocolitis and one of a 1,380 g infant from hydro-
cephalus and brain atrophy). 
Discussion 
This study has shown that rhEPO at a subcutaneous dose of 70 U/kg/week 
is safe in preterm infants. Treatment with this regimen did not affect haema-
tocrit, haemoglobin or volume of red cells transfused per kilogram birth 
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Table 4. Iron administration up to day 25 
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Infants without Infants treated Mean cumulated 
any iron, n with iron, n iron dose (mg) in 
iron-treated infants 
Münster 1 18 25 
Heidelberg 6 10 17 
Glasgow 1 17 53 
Berlin-Charite 4 6 31 
Berlin-West 2 18 30 
All 14 69 32 
l i t e i 
46.9 : 44.1: 25.5 V: 17.1: 16.6 12.5: 
500-999 1,000-1,499 
Birth weight, g 
> 1,499 
Fig. 5. Total blood volume sampled up to day 25 (ml/kg birth weight; median ± quar-
tiles), according to birth weight and stratification. • = Artificial ventilation; • = spontaneous 
breathing. 
weight. Although reticulocyte counts in infants receiving rhEPO were slightly 
higher than in the control infants at days 13 and 25, this failed to reach 
statistical significance. The expected fall in serum ferritin concentration did 
not occur, confirming that rhEPO given to preterm infants at this dose was not 
effective. Shannon et al. [16] in a double-blind placebo-controlled study ad-
ministering 100 U/kg twice weekly to treat the anaemia of prematurity also 
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TableS. Major reasons for discontinuation of the study in 10 infants, explaining the total 
number of 83 infants in tables 2 - 4 (only one reason is indicated per infant) 
Stop rule rhEPO Control 
Death 0 1 
Hct >50%, Hb >17 g/dl 3 0 
Platelets >600 x lO3/! 1 0 
Renal failure 0 1 
Exchange transfusion 0 1 
Consent withdrawal 1 1 
Others (transfer) 0 1 
All 5 5 
rhEPO = rhEPO-treated group; control = control group. 
Table 6. Incidence of complicating disorders of prematurity, independent of discontinuation 
of the trial 
Complications rhEPO (n = 43) Control (n = 50) 
Necrotizing enterocolitis 1 3 
Patent ductus arteriosus 1 3 
Intraventricular haemorrhage 5 5 
Bronchopulmonary dysplasia 6 5 
All complicating disorders 13 16 
rhEPO = rhEPO-treated group; control = control group. 
failed to show a response. This failure to demonstrate a haemopoietic re-
sponse may be due to inadequate dosage, suboptimal nutrition including iron 
deficiency, inflammation, infection, or the requirement for other growth fac-
tors. 
Premature infants may generally require larger doses of rhEPO than 
older children and adults: in an animal study using rhesus monkeys, George et 
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al. [17] found that rhEPO doses of 100 or 250 U/kg, applied twice weekly, 
produced significant increases in haemoglobin in adults, but no change in 
newborn animals. Oster et al. [18] used doses of 300-600 U/kg/week to prevent 
chemotherapy-induced anaemia, Niemeyer [19] has used doses of up to 
2,000 U/kg daily in an attempt to treat Blackfan-Diamond disease. EPO has 
been used in a dose of 1,200 U/kg/week to increase preoperative collection of 
autologous blood [20]. Halperin et al. [21] in a recent uncontrolled pilot study 
reported an increase in reticulocytes and stabilization of haematocrit in pre-
term infants treated with higher doses (up to 300 U/kg/week) of EPO. How-
ever, since the EPO treatment was started after the 3rd week of life, the infants 
were slightly more mature; therefore, Halp6rin's study was different from ours 
not only in terms of EPO dosage. It cannot be excluded that the positive 
response was due to a normal development of reticulocytes and haematocrit at 
this age. 
Ohls et al. [22] studied the erythroid 'burst-promoting' activity in the 
serum of patients with the anaemia of prematurity. Burst-promoting activity 
was similar to that found in adult blood and cord sera. Their findings indicate 
that the anaemia of prematurity like the anaemia of end-stage renal disease is 
associated with a specific deficiency of EPO. 
The erythropoietic potential of a fetus gaining weight from 1 to 3 kg is 
90 ml red cells. If this potential is to be realized, maintenance of nutritional 
status, especially with regard to haematopoiesis, will be important. Achieve-
ment of optimal erythropoiesis should reduce the requirement for donor 
transfusion whilst maintaining blood volume for optimal oxygen delivery and 
tissue perfusion. Maintenance of this physiological state of the blood is also 
likely to minimize the complications of preterm delivery, especially those 
related to inadequate oxygenation and perfusion by the blood such as pro-
longed dependence on respiratory support [7]. For these reasons we believe 
that controlled studies with higher doses of rhEPO are now indicated in 
preterm infants. 
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